Moderna and Merck announced that their experimental mRNA vaccine successfully prevented the return and spread of melanoma in high-risk patients. The vaccine targets specific genetic mutations found in melanoma tumors, helping the immune system recognize and attack cancer cells before they can regrow.

In clinical trials, patients who received the vaccine showed significantly lower rates of cancer recurrence compared to those who did not. The treatment was particularly effective in individuals with advanced-stage disease, where the risk of melanoma returning is highest.

The vaccine works by using mRNA technology to instruct cells to produce proteins that trigger an immune response against melanoma. This approach builds on the success of mRNA vaccines developed for infectious diseases, adapting the platform for cancer immunotherapy.

Moderna and Merck plan to submit regulatory applications for the vaccine within the next year. If approved, the treatment could become a new standard of care for melanoma patients at high risk of recurrence, offering hope for improved long-term outcomes.